LGVN vs. ORMP, IMUX, CLLS, CTOR, ALTS, IGMS, DBVT, ADAG, AVTX, and TNYA
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Oramed Pharmaceuticals (ORMP), Immunic (IMUX), Cellectis (CLLS), Citius Oncology (CTOR), Janone (ALTS), IGM Biosciences (IGMS), DBV Technologies (DBVT), Adagene (ADAG), Avalo Therapeutics (AVTX), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry.
Longeveron vs.
Oramed Pharmaceuticals (NASDAQ:ORMP) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.
In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Longeveron. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 0 mentions for Longeveron. Oramed Pharmaceuticals' average media sentiment score of 0.25 beat Longeveron's score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.
Longeveron has a consensus price target of $8.67, suggesting a potential upside of 470.18%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Oramed Pharmaceuticals.
Oramed Pharmaceuticals has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Oramed Pharmaceuticals received 303 more outperform votes than Longeveron when rated by MarketBeat users. However, 94.12% of users gave Longeveron an outperform vote while only 72.83% of users gave Oramed Pharmaceuticals an outperform vote.
Oramed Pharmaceuticals has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.
12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 13.7% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 19.1% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Oramed Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. Oramed Pharmaceuticals' return on equity of -7.27% beat Longeveron's return on equity.
Summary
Oramed Pharmaceuticals beats Longeveron on 13 of the 19 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Longeveron Competitors List
Related Companies and Tools
This page (NASDAQ:LGVN) was last updated on 2/10/2025 by MarketBeat.com Staff